Skip to main content

Advertisement

Table 2 Results of repeat imaging at day 22

From: Oral rivaroxaban for Japanese patients with symptomatic venous thromboembolism – the J-EINSTEIN DVT and PE program

  Rivaroxaban 10 mg bid/15 mg od Rivaroxaban 15 mg bid/15 mg od Rivaroxaban combined UFH/warfarin
DVT patients N = 23 N = 24 N = 47 N = 12
Improved or normalized, n (%) 18 (78.3) 18 (75.0) 36 (76.6) 10 (83.3)
         Normalized 4 (17.4) 6 (25.0) 10 (21.3) 2 (16.7)
Unchanged, n (%) 4 (17.4) 5 (20.8) 9 (19.1) 2 (16.7)
Deteriorated, n (%) 1 (4.3) 1 (4.2) 2 (4.3) 0
         Asymptomatic 1 (4.3) 0 1 (2.1) 0
         Symptomatic* 0 1 (4.2) 1 (2.1) 0
PE patients N = 28 N = 28 N = 7
Improved or normalized, n (%) 27 (96.4) 27 (96.4) 7 (100)
         Normalized   10 (35.7) 10 (35.7) 1 (14.3)
Unchanged, n (%) 0 0 0
Deteriorated, n (%) 1 (3.6) 1 (3.6) 0
         Asymptomatic   1 (3.6) 1 (3.6) 0
         Symptomatic*   0 0 0
DVT and PE patients N = 23 N = 52 N = 75 N = 19
Improved or normalized, n (%) 18 (78.3) 45 (86.5) 63 (84.0) 17 (89.5)
         Normalized 4 (17.4) 16 (30.8) 20 (26.7) 3 (15.8)
Unchanged, n (%) 4 (17.4) 5 (9.6) 9 (12.0) 2 (10.5)
Deteriorated, n (%) 1 (4.3) 2 (3.8) 3 (4.0) 0
         Asymptomatic 1 (4.3) 1 (1.9) 2 (2.7) 0
         Symptomatic* 0 1 (1.9) 1 (1.3) 0
  1. bid, twice daily, DVT, deep vein thrombosis; od, once daily; PE, pulmonary embolism; UFH, unfractionated heparin; VTE, venous thromboembolism.
  2. *Symptomatic recurrent VTE during first 22 days.